Studying health outcomes in people with myelofibrosis
Part of Blood & lymphatic clinical trials.
This study collects information from people diagnosed with myelofibrosis to understand how the disease affects them over time. It may help researchers learn more about the condition and improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary myelofibrosis or myelofibrosis that started after another blood disorder like ET or PV.
- You were diagnosed between January 1, 2018, and December 31, 2027.
- You are 18 years old or older.
- You are willing to sign a consent form allowing your health data to be used for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with myelofibrosis and anemia who are starting a new treatment. It aims to learn more about the disease and how treatments work in real life.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial tests a combination of two oral medications for people with myelofibrosis, a type of bone marrow cancer. It may be an option if you have not been helped by standard JAK inhibitor therapy or if you have never tried one.
This observational registry tracks symptoms, treatments, and disease changes over time in people diagnosed with myeloproliferative neoplasms (MPNs). By joining, you help doctors learn more about the condition and possibly contribute to better future care.
This trial studies whether an allogeneic (donor) stem cell transplant can help people with higher-risk myelofibrosis (fibrosis in the bone marrow). It looks at outcomes in different donor types as determined by matching rules and patient risk level.
This trial tests two oral medications, momelotinib and ruxolitinib, to see which works better for people with newly diagnosed myelofibrosis who also have low blood cell counts. You may be able to join if your spleen is enlarged and you haven't had prior treatment with certain drugs.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.